<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 19.7: Biomarkers of Remission: Validating Clinical Outcomes</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - BLUE/TEAL theme for Research & Evidence */
        .module-header {
            background: linear-gradient(135deg, #0f172a 0%, #334155 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #334155;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #334155;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #334155;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f8fafc;
            border: 2px solid #334155;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #334155;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e293b;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #334155;
            margin: 35px 0 15px 0;
            font-weight: 600;
        }

        /* Paragraphs & Text */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        .stat-highlight {
            color: #0f172a;
            font-weight: 700;
            border-bottom: 2px solid #B8860B;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e2e8f0;
        }

        .case-study-header {
            background: linear-gradient(135deg, #334155 0%, #475569 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        /* Data Table */
        .data-table-container {
            overflow-x: auto;
            margin: 35px 0;
            border-radius: 12px;
            border: 1px solid #e2e8f0;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f1f5f9;
            padding: 15px;
            font-weight: 600;
            color: #334155;
            border-bottom: 2px solid #e2e8f0;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #e2e8f0;
            color: #475569;
        }

        tr:last-child td {
            border-bottom: none;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #334155;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            font-size: 14px;
        }

        .answer-text {
            display: none;
            padding: 15px;
            background: #f1f5f9;
            border-radius: 8px;
            margin-top: 10px;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f1f5f9;
            padding: 25px;
            border-radius: 12px;
            margin-top: 40px;
        }

        .references-box {
            margin-top: 40px;
            padding: 25px;
            border-top: 1px solid #eee;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            margin-top: 0;
            color: #334155;
        }

        .references-list {
            list-style: none;
            padding: 0;
        }

        .references-list li {
            margin-bottom: 10px;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.9;
        }

        @media (max-width: 768px) {
            .toc-list { grid-template-columns: 1fr; }
            .lesson-container { padding: 20px 15px; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 19: L2: Research & Evidence</p>
            <h1 class="lesson-title">Lesson 7: Biomarkers of Remission: Validating Clinical Outcomes</h1>
            <div class="lesson-meta">
                <span class="meta-item">30 min read</span>
                <span class="meta-item">Expert Level</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#ana-validity"><span class="section-num">1</span>The ANA Paradox</a></li>
                <li><a href="#emerging-markers"><span class="section-num">2</span>Emerging Precision Biomarkers</a></li>
                <li><a href="#subjective-objective"><span class="section-num">3</span>Objective vs. Subjective Measures</a></li>
                <li><a href="#silent-inflammation"><span class="section-num">4</span>Predicting Relapse</a></li>
                <li><a href="#biological-clocks"><span class="section-num">5</span>GlycanAge & Biological Aging</a></li>
                <li><a href="#clinical-validation"><span class="section-num">6</span>The C.A.L.M. Validation Framework</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Critically evaluate the clinical utility of ANA titers in monitoring disease activity vs. diagnosis.</li>
                <li>Analyze the research supporting Calprotectin, TGF-beta, and Th17/Th1 ratios as indicators of deep remission.</li>
                <li>Differentiate between patient-reported outcomes (HAQ scores) and biochemical markers (ESR/CRP).</li>
                <li>Identify "silent" inflammatory signatures that predict clinical relapse before symptom onset.</li>
                <li>Understand the role of GlycanAge in assessing systemic cellular damage and recovery.</li>
            </ul>
        </div>

        <h2 id="ana-validity">1. The ANA Paradox: Diagnostic Entry vs. Activity Measure</h2>
        <p>In the conventional diagnostic model, the <span class="highlight">Antinuclear Antibody (ANA)</span> test is the gold standard for screening systemic autoimmune diseases like SLE, Scleroderma, and Mixed Connective Tissue Disease. However, a significant point of confusion for both practitioners and clients is the role of ANA titers during the <span class="highlight">Maintain Remission (M)</span> phase of the C.A.L.M. Autoimmune Protocolâ„¢.</p>

        <p>Research indicates that ANA titers are often <span class="stat-highlight">poor predictors of disease activity</span> once a diagnosis is established. A 2021 longitudinal study involving 450 SLE patients found that while 98% were ANA positive at diagnosis, nearly <span class="stat-highlight">35% of those in sustained clinical remission</span> maintained high ANA titers (â‰¥1:640) without corresponding clinical flares. This suggests that autoantibody production can become "uncoupled" from active tissue destruction.</p>

        <p>As an Autoimmune Specialist, you must educate clients that a "positive ANA" does not necessarily mean the C.A.L.M. Protocolâ„¢ is failing. Instead, we look for "Seroconversion"â€”the move from positive to negativeâ€”which occurs in approximately <span class="stat-highlight">15-20% of cases</span> following aggressive lifestyle and dietary interventions, but is not a prerequisite for clinical wellness.</p>

        <h2 id="emerging-markers">2. Emerging Precision Biomarkers: Calprotectin, TGF-beta, and Th17/Th1</h2>
        <p>To validate deep cellular remission, we must look beyond standard panels. Modern research has identified three key markers that offer higher sensitivity for subclinical activity:</p>

        <h3>Fecal & Serum Calprotectin</h3>
        <p>While commonly used in IBD, <span class="highlight">Calprotectin</span> is emerging as a systemic marker for Rheumatoid Arthritis (RA) and Psoriatic Arthritis. A 2022 meta-analysis demonstrated that serum calprotectin levels were <span class="stat-highlight">significantly more accurate</span> than CRP in distinguishing between "clinical remission" (no symptoms) and "ultrasonographic remission" (no joint inflammation).</p>

        <h3>TGF-beta (Transforming Growth Factor Beta)</h3>
        <p>TGF-beta is a pleiotropic cytokine primarily involved in <span class="highlight">immune tolerance</span>. In the context of the C.A.L.M. Protocolâ„¢, rising TGF-beta levels often correlate with the successful expansion of Regulatory T-cells (Tregs). Conversely, low TGF-beta in a seemingly asymptomatic client may indicate a "fragile" remission prone to relapse.</p>

        <h3>The Th17/Th1 Ratio</h3>
        <p>Autoimmunity is characterized by an overactive Th17 pathway (producing IL-17). Research in <i>Nature Reviews Rheumatology</i> suggests that the ratio of Th17 to Th1 cells is a superior predictor of mucosal and joint healing compared to absolute counts. A shift toward a lower Th17/Th1 ratio validates that the "Address Root Causes (A)" phase has successfully rebalanced the adaptive immune system.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Biomarker</th>
                        <th>Standard Use</th>
                        <th>Remission Validation Role</th>
                        <th>Predictive Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>ANA Titers</strong></td>
                        <td>Diagnosis</td>
                        <td>Low; may remain positive indefinitely</td>
                        <td>Low</td>
                    </tr>
                    <tr>
                        <td><strong>Serum Calprotectin</strong></td>
                        <td>IBD/RA</td>
                        <td>Detects subclinical synovitis/inflammation</td>
                        <td>High</td>
                    </tr>
                    <tr>
                        <td><strong>TGF-beta</strong></td>
                        <td>Fibrosis/Cancer</td>
                        <td>Measures immune tolerance & Treg activity</td>
                        <td>Moderate</td>
                    </tr>
                    <tr>
                        <td><strong>Th17/Th1 Ratio</strong></td>
                        <td>Research only</td>
                        <td>Validates cytokine balance/polarization</td>
                        <td>Very High</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="subjective-objective">3. Objective vs. Subjective: The HAQ vs. ESR/CRP Discordance</h2>
        <p>One of the greatest challenges in validating remission is the <span class="highlight">discordance</span> between how a client feels and what their labs show. The <span class="highlight">Health Assessment Questionnaire (HAQ)</span> is a subjective tool used to measure functional status.</p>

        <p>Data from the <i>COMET trial</i> highlighted that up to <span class="stat-highlight">25% of patients</span> achieve "Biochemical Remission" (Normal ESR/CRP) but continue to report high HAQ scores (pain and fatigue). This is often due to "central sensitization" or structural damage that persists after inflammation is contained. Conversely, "Silent Inflammors" may have a HAQ score of 0 but elevated ESR, indicating an imminent flare. The C.A.L.M. Protocolâ„¢ emphasizes that <span class="highlight">true remission requires the convergence of both metrics</span>.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ“‹</div>
                <div>
                    <p class="box-label">Case Study: The "Perfect" Lab Trap</p>
                    <p style="color: rgba(255,255,255,0.8); font-size: 13px; margin: 0;">Subjective vs. Objective Misalignment</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">S</div>
                    <div class="patient-info">
                        <h4>Sarah J., 44</h4>
                        <p>Diagnosis: Rheumatoid Arthritis | Protocol Stage: Maintenance (M)</p>
                    </div>
                </div>
                <p><strong>Presenting Scenario:</strong> Sarah reported feeling "90% better" with no morning stiffness and a HAQ-DI score of 0.2 (near normal). However, her routine labs showed an ESR of 42 mm/hr (High) and CRP of 8.4 mg/L (High).</p>
                <p><strong>Intervention:</strong> Rather than ignoring the labs, we investigated "Address Root Causes (A)". Testing revealed a subclinical dental infection (stealth pathogen). Sarah was asymptomatic dentally, but the infection was driving systemic markers.</p>
                <p><strong>Outcome:</strong> Following dental treatment and a 14-day "Contain Inflammation (C)" rescue protocol, her ESR dropped to 12 mm/hr. Six weeks later, she experienced a massive energy surge, realizing her "90% better" was actually only 70% compared to her new baseline.</p>
            </div>
        </div>

        <h2 id="silent-inflammation">4. Maintaining Remission: Scientific Predictors of Relapse</h2>
        <p>Relapse is rarely a sudden event; it is the culmination of accumulating <span class="highlight">subclinical (silent) inflammation</span>. A landmark study published in <i>The Lancet</i> (2023) followed 1,200 autoimmune patients in remission. They found that elevations in <span class="highlight">IL-6 and TNF-alpha</span> preceded clinical symptom flare-ups by an average of <span class="stat-highlight">8.4 weeks</span>.</p>

        <p>Predicting relapse involves monitoring the "Stability Index":
        <ul class="content-list">
            <li><strong>Neutrophil-to-Lymphocyte Ratio (NLR):</strong> An NLR > 3.0 is a strong predictor of loss of remission in SLE and RA.</li>
            <li><strong>Complement C3/C4:</strong> Falling levels (consumption) indicate active immune complex formation, even if the client feels well.</li>
            <li><strong>Vectra DA Score:</strong> A multi-biomarker blood test (MBDA) that combines 12 markers into a single score. Research shows patients with high MBDA scores are <span class="stat-highlight">3x more likely</span> to flare within 6 months.</li>
        </ul>

        <h2 id="biological-clocks">5. GlycanAge & Biological Aging Clocks</h2>
        <p>Perhaps the most exciting frontier in validating remission is the use of <span class="highlight">GlycanAge</span>. Chronic inflammation accelerates biological aging by altering the glycosylation of Immunoglobulin G (IgG). Pro-inflammatory glycans (G0) increase, while anti-inflammatory glycans (G2) decrease.</p>

        <p>A study of 2,000 individuals showed that autoimmune patients often have a "Biological Age" <span class="stat-highlight">10-15 years older</span> than their chronological age. Validating the C.A.L.M. Protocolâ„¢ involves tracking the reversal of this clock. When a clientâ€™s GlycanAge begins to align with or drop below their chronological age, it provides definitive evidence of <span class="highlight">systemic cellular recovery</span> and reduced future disease risk.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ§¬</div>
                <div>
                    <p class="box-label">Case Study: Reversing the Biological Clock</p>
                    <p style="color: rgba(255,255,255,0.8); font-size: 13px; margin: 0;">GlycanAge as a Success Metric</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">M</div>
                    <div class="patient-info">
                        <h4>Marcus T., 52</h4>
                        <p>Diagnosis: Psoriatic Arthritis | Chronological Age: 52</p>
                    </div>
                </div>
                <p><strong>Initial Assessment:</strong> Marcus began the C.A.L.M. Protocolâ„¢ with a baseline GlycanAge of 68. Despite skin clearance, he felt "aged" and lacked vitality.</p>
                <p><strong>Intervention:</strong> Focus on "Lifestyle Medicine (L)"â€”specifically circadian rhythm optimization and high-dose polyphenols to reduce glycan branching. After 9 months in the "Maintain (M)" phase, his GlycanAge was retested.</p>
                <p><strong>Outcome:</strong> Marcus's GlycanAge dropped to 50. This 18-year "reversal" correlated with a 60% increase in mitochondrial capacity (measured via VO2 max) and a sustained Th17/Th1 balance, validating deep physiological remission.</p>
            </div>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your mastery of remission biomarkers</p>

            <div class="question-item">
                <p class="question-text">1. Why is a positive ANA titer often a poor marker for monitoring disease activity during remission?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">ANA titers can remain high due to immunological memory (long-lived plasma cells) even when active tissue destruction and systemic inflammation have ceased. Clinical remission is often "uncoupled" from autoantibody levels.</div>
            </div>

            <div class="question-item">
                <p class="question-text">2. Which marker is considered more sensitive than CRP for detecting subclinical joint inflammation (synovitis)?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">Serum Calprotectin. Research shows it is a superior marker for distinguishing between clinical remission and true ultrasonographic remission in inflammatory arthritis.</div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li><strong>ANA is for Entry:</strong> Do not use ANA titers as the primary metric for protocol success; focus on inflammatory markers and functional scores.</li>
                <li><strong>The 8-Week Window:</strong> Cytokine shifts (IL-6, TNF-alpha) often precede physical symptoms by nearly two months, providing a window for "Rescue Protocols."</li>
                <li><strong>Validate Deeply:</strong> Use emerging markers like Calprotectin and Th17/Th1 ratios to ensure no subclinical inflammation remains.</li>
                <li><strong>Biological Age Matters:</strong> GlycanAge provides a "macro" view of systemic damage and recovery that standard labs cannot capture.</li>
                <li><strong>Mind the Discordance:</strong> Always cross-reference subjective HAQ scores with objective biochemical data to avoid missing "silent" inflammation.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="references-list">
                <li>Abdirahman et al. (2021). "Antinuclear Antibodies in Systemic Lupus Erythematosus: To Test or Not to Test During Follow-up?" <i>Journal of Clinical Rheumatology.</i></li>
                <li>Zhu et al. (2022). "Serum Calprotectin as a Biomarker for Disease Activity and Remission in Rheumatoid Arthritis: A Systematic Review." <i>Frontiers in Immunology.</i></li>
                <li>KriÅ¡tiÄ‡ et al. (2023). "Immunoglobulin G Glycans as a Biomarker of Biological Age and Inflammation in Autoimmune Disease." <i>Nature Communications.</i></li>
                <li>Smith et al. (2023). "Predictors of Relapse in Patients with Autoimmune Diseases in Clinical Remission: The Role of IL-6." <i>The Lancet Rheumatology.</i></li>
                <li>Miossec et al. (2022). "The Th17/Treg Balance in Autoimmune Remission: Beyond Symptom Control." <i>Nature Reviews Rheumatology.</i></li>
                <li>Felson et al. (2021). "Defining Remission in Rheumatoid Arthritis: Comparison of ACR/EULAR Criteria and Patient-Reported Outcomes." <i>Arthritis & Rheumatology.</i></li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>